Table 1.
Distributions of baseline variables by treatment arm, according to prognostic Okuda subgroups
| Okuda category | I-II | III or unknown | ||
| Tamoxifen (n = 189) | Control (n = 196) | Tamoxifen (n = 48) | Control (n = 44) | |
| Median (range) age, years | 66 (39–91) | 67 (42–84) | 62 (37–86) | 66 (31–80) |
| Men | 133 (70.4) | 144 (73.5) | 36 (75.0) | 39 (88.6) |
| Evidence of disease at entry | 178 (94.2) | 184 (93.9) | 40 (83.3) | 39 (88.6) |
| Interval between diagnosis and entry | ||||
| 0–6 months | 150 (79.4) | 161 (82.1) | 44 (91.7) | 38 (86.7) |
| 7–12 months | 20 (10.6) | 15 (7.7) | 1 (2.1) | 4 (9.1) |
| 13–24 months | 19 (10.1) | 20 (10.2) | 6 (6.3) | 2 (4.6) |
| Child-Pugh category | ||||
| A | 90 (47.6) | 98 (50.0) | 25 (52.1) | 20 (45.6) |
| B | 82 (43.4) | 75 (38.3) | 13 (27.1) | 11 (25.0) |
| C | 17 (9.0) | 23 (11.7) | 9 (18.8) | 12 (27.3) |
| unknown | 0 (0.0) | 0 (0.0) | 1 (2.1) | 1 (2.3) |
| Locoregional treatment | ||||
| Surgery | 11 (5.8) | 12 (6.1) | 7 (14.6) | 3 (6.8) |
| Percutaneous Ethanol Injection | 61 (32.3) | 72 (36.7) | 3 (6.3) | 6 (13.6) |
| Transarterial chemoembolization | 31 (16.4) | 33 (16.8) | 11 (22.9) | 5 (11.4) |
| none | 86 (45.5) | 79 (40.3) | 27 (56.3) | 30 (68.2) |